Specifically, while anti-TNFα therapy is an effective treatment for Inflammatory Bowel Disease (IBD) and rheumatoid arthritis (RA), it paradoxically induces exacerbations in patients with MS30,31. The gene discussed is TNF; the disease is rheumatoid arthritis.